[go: up one dir, main page]

SV2010003458A - Compuestos y metodos para modular el receptor farnesoide x (fxr) - Google Patents

Compuestos y metodos para modular el receptor farnesoide x (fxr)

Info

Publication number
SV2010003458A
SV2010003458A SV2010003458A SV2010003458A SV2010003458A SV 2010003458 A SV2010003458 A SV 2010003458A SV 2010003458 A SV2010003458 A SV 2010003458A SV 2010003458 A SV2010003458 A SV 2010003458A SV 2010003458 A SV2010003458 A SV 2010003458A
Authority
SV
El Salvador
Prior art keywords
methods
compounds
farnesoid
fxr
modulate
Prior art date
Application number
SV2010003458A
Other languages
English (en)
Inventor
Michael James Genin
Francisco Javier Agejas-Chicharro
Melendo Ana Belen Bueno
Peter Rudolph Manninen
Ala M Warshawsky
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2010003458A publication Critical patent/SV2010003458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

COMPUESTOS DE FÓRMULA: (VE FORMULA); EN DONDE LAS VARIABLES SON COMO SE DEFINEN EN ESTE DOCUMENTO Y SUS COMPOSICIONES FARMACÉUTICAS Y MÉTODOS PARA USO SE DESCRIBEN COMO ÚTILES PARA TRATAR DISLIPIDEMIA Y ENFERMEDADES RELACIONADAS A DISLIPIDEMIA
SV2010003458A 2007-07-16 2010-01-15 Compuestos y metodos para modular el receptor farnesoide x (fxr) SV2010003458A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16

Publications (1)

Publication Number Publication Date
SV2010003458A true SV2010003458A (es) 2011-01-10

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003458A SV2010003458A (es) 2007-07-16 2010-01-15 Compuestos y metodos para modular el receptor farnesoide x (fxr)

Country Status (31)

Country Link
US (1) US8153624B2 (es)
EP (1) EP2178851B1 (es)
JP (1) JP5373788B2 (es)
KR (1) KR101157334B1 (es)
CN (1) CN101743232B (es)
AR (1) AR067540A1 (es)
AT (1) ATE539065T1 (es)
AU (1) AU2008276236B2 (es)
BR (1) BRPI0814571A2 (es)
CA (1) CA2693406C (es)
CL (1) CL2008002051A1 (es)
CO (1) CO6270212A2 (es)
CY (1) CY1112298T1 (es)
DK (1) DK2178851T3 (es)
DO (1) DOP2010000018A (es)
EA (1) EA016475B1 (es)
EC (1) ECSP109879A (es)
ES (1) ES2376176T3 (es)
HR (1) HRP20120048T1 (es)
IL (1) IL202234A0 (es)
MA (1) MA31683B1 (es)
MX (1) MX2010000502A (es)
PE (1) PE20090809A1 (es)
PL (1) PL2178851T3 (es)
PT (1) PT2178851E (es)
RS (1) RS52216B (es)
SI (1) SI2178851T1 (es)
SV (1) SV2010003458A (es)
TN (1) TN2010000028A1 (es)
TW (1) TW200906823A (es)
WO (1) WO2009012125A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012087521A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
US20130261108A1 (en) * 2010-12-20 2013-10-03 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
KR101949251B1 (ko) 2013-09-11 2019-02-18 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) B형간염바이러스 감염의 치료 방법 및 치료용 약학적 조성물
LT3065738T (lt) * 2013-11-05 2018-05-10 Novartis Ag Kompozicijos ir būdai, skirti x receptorių moduliavimui
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
TN2017000344A1 (en) 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
ES2886766T3 (es) 2015-03-31 2021-12-20 Enanta Pharm Inc Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos
MX2017012893A (es) 2015-04-07 2018-01-15 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas.
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
KR20180124123A (ko) 2016-03-28 2018-11-20 인터셉트 파마슈티컬즈, 인크. Fxr 효능제 및 arb의 조합에 의해 얻어지는 의약
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
JP7093341B2 (ja) * 2016-08-23 2022-06-29 アルデリックス， インコーポレイテッド 代謝異常状態及び代謝障害を治療するためのホルモン受容体調節薬
WO2018051229A1 (en) * 2016-09-14 2018-03-22 Novartis Ag Novel regimes of fxr agonists
JP2019537557A (ja) 2016-10-04 2019-12-26 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
CN110944635A (zh) 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
CN110678450B (zh) * 2017-04-12 2023-06-20 日东制药株式会社 作为核受体激动剂的异噁唑衍生物及其用途
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
CN111655680B (zh) 2017-09-14 2024-03-05 阿德利克斯股份有限公司 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂
CA3081424A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
AR113820A1 (es) * 2017-11-01 2020-06-17 Bristol Myers Squibb Co Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
KR102732404B1 (ko) * 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 알켄 화합물
WO2019089664A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
KR102732405B1 (ko) 2017-11-01 2024-11-20 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN111263759B (zh) * 2017-12-22 2023-03-28 四川科伦博泰生物医药股份有限公司 异噁唑衍生物及其制备方法和用途
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
MX2021002305A (es) * 2018-08-30 2021-05-31 Terns Pharmaceuticals Inc Tratamiento de trastornos del higado.
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
KR102883856B1 (ko) 2019-02-15 2025-11-10 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
SG11202108794RA (en) 2019-02-15 2021-09-29 Bristol Myers Squibb Co Substituted amide compounds useful as farnesoid x receptor modulators
EP3924337A1 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid x receptor modulators
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
KR20220003558A (ko) 2019-04-19 2022-01-10 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Fxr 소분자 작용제 및 이의 제조 방법과 용도
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
KR20220016146A (ko) 2019-05-30 2022-02-08 인터셉트 파마슈티컬즈, 인크. 담즙정체성 간 질환의 치료에서 사용하기 위한 fxr 효능제 및 피브레이트를 포함하는 제약 조성물
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114667142A (zh) * 2019-11-08 2022-06-24 拓臻制药公司 治疗肝脏病症
WO2021108974A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
ES3014367T3 (en) 2020-01-15 2025-04-22 Inst Nat Sante Rech Med Use of fxr agonists for treating an infection by hepatitis d virus
KR20230024277A (ko) * 2020-05-13 2023-02-20 테른스 파마슈티칼스, 인크. 간 장애의 조합 치료
EP4204405A4 (en) 2020-08-25 2024-05-29 Eli Lilly and Company POLYMORPHS OF AN SSAO INHIBITOR
WO2022056238A1 (en) * 2020-09-11 2022-03-17 Terns Pharmaceuticals, Inc. Solid dispersion formulations of an fxr agonist
JP2023547597A (ja) * 2020-10-15 2023-11-13 イーライ リリー アンド カンパニー Ｆｘｒアゴニストの多形
EP4277622A1 (en) 2021-01-14 2023-11-22 ENYO Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN119013027A (zh) 2021-11-11 2024-11-22 拓臻制药公司 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis
CN115850152B (zh) * 2022-12-20 2025-10-31 河北鼎泰制药有限公司 一种杂质A-7-imp3的制备方法及其用途
EP4568664A1 (en) 2023-04-07 2025-06-18 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
NZ537251A (en) 2002-07-09 2007-02-23 Bristol Myers Squibb Co Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
EP1562915A1 (en) 2002-11-22 2005-08-17 SmithKline Beecham Corporation Farnesoid x receptor agonists
US7863302B2 (en) * 2006-02-03 2011-01-04 Eli Lilly And Company Compounds and methods for modulating FX-receptors
BRPI0712262A2 (pt) * 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
DE602007005256D1 (de) 2006-05-24 2010-04-22 Lilly Co Eli Verbindungen und verfahren zur modulierung von fx-rezeptoren

Also Published As

Publication number Publication date
MX2010000502A (es) 2010-03-26
CA2693406C (en) 2014-04-29
ATE539065T1 (de) 2012-01-15
US8153624B2 (en) 2012-04-10
DK2178851T3 (da) 2012-02-06
CA2693406A1 (en) 2009-01-22
EP2178851B1 (en) 2011-12-28
HRP20120048T1 (hr) 2012-02-29
KR101157334B1 (ko) 2012-06-15
JP5373788B2 (ja) 2013-12-18
ES2376176T3 (es) 2012-03-09
SI2178851T1 (sl) 2012-02-29
WO2009012125A1 (en) 2009-01-22
AU2008276236A1 (en) 2009-01-22
ECSP109879A (es) 2010-02-26
JP2010533722A (ja) 2010-10-28
DOP2010000018A (es) 2010-01-31
CN101743232A (zh) 2010-06-16
EP2178851A1 (en) 2010-04-28
CN101743232B (zh) 2013-03-06
CL2008002051A1 (es) 2009-05-29
TW200906823A (en) 2009-02-16
AR067540A1 (es) 2009-10-14
KR20100020999A (ko) 2010-02-23
RS52216B (sr) 2012-10-31
EA016475B1 (ru) 2012-05-30
CO6270212A2 (es) 2011-04-20
PL2178851T3 (pl) 2012-05-31
PE20090809A1 (es) 2009-06-27
TN2010000028A1 (en) 2011-09-26
CY1112298T1 (el) 2015-12-09
IL202234A0 (en) 2010-06-16
PT2178851E (pt) 2012-02-27
MA31683B1 (fr) 2010-09-01
EA201070148A1 (ru) 2010-06-30
AU2008276236B2 (en) 2013-03-14
US20100152166A1 (en) 2010-06-17
BRPI0814571A2 (pt) 2015-01-06

Similar Documents

Publication Publication Date Title
SV2010003458A (es) Compuestos y metodos para modular el receptor farnesoide x (fxr)
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
NI201000119A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.
BRPI0813695A2 (pt) Heteroaril piridil e fenila benzenossulfonamidas fundidas como moduladores de ccr2 para o tratamento de inflamação
UY30748A1 (es) Compuesto0s novedosos
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CL2007001451A1 (es) Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas.
NI200700221A (es) Antagonistas receptor pgd2 para el tratamiento de enfermedades inflamatorias
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
CY1111807T1 (el) Παραγωγα βενζοθειαζεπινης και η χρηση τους ως ρυθμιστων των υποδοχεων ampα και nmda
CR9956A (es) Metodos y composiciones para modular la hemostasia
UY31561A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR10545A (es) Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
SV2009003300A (es) Nuevos herbicidas
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
DOP2007000018A (es) Moduladores de indol sulfonamida de receptores de progesterona
CR10213A (es) Moduladores de la proteína quinasa aurora
UY30304A1 (es) Moduladores de mglur5 i
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
UY30610A1 (es) Moduladores de mglur5
DOP2011000272A (es) Derivados de pirazolo usados como antagonistas receptores de ccr4

Legal Events

Date Code Title Description
FD Lapse